Answers are grounded in this paper and cite their sources.
Retrospective study evaluates CCND1 IHC for detecting t(11;14) in AL amyloidosis, suggesting reliable screening tool.
Systemic immunoglobulin light chain (AL) amyloidosis is a monoclonal disorder arising from late B-lymphocyte lineage progenitors, in which normally soluble immunoglobulin light chains misfold and form amyloid fibrils that deposit in tissues and cause end-organ dysfunction.1, 2 Although contemporary daratumumab-based regimens, as demonstrated in the ANDROMEDA clinical trial, have significantly improved outcomes, up to one-third of patients require subsequent therapy due to inadequate haematological responses.2-5 The chromosomal translocation t(11;14)(q13;q32), which juxtaposes the proto-oncogene cyclin D1 (CCND1) with the immunoglobulin heavy chain (IgH) locus, is the most common cytogenetic abnormality in AL amyloidosis, occurring in ~50% of cases.2 Although the presence of t(11;14) has been associated with adverse outcomes in patients treated with bortezomib-based regimens, this negative impact appears to be abrogated by melphalan- and daratumumab-based therapies.2, 3 Cells harbouring t(11;14) exhibit a biologically distinct phenotype, characterized by primed apoptotic pathways and an increased dependence on the pro-survival protein B-cell Lymphoma 2 (BCL-2).6 This dependency enables therapeutic targeting with BCL-2 inhibitors.2, 6 Fluorescence in situ hybridization (FISH) is the gold standard for detecting t(11;14), but its accuracy relies on obtaining a high-quality bone marrow aspirate with sufficient clonal plasma cells.7, 8 This can be particularly challenging in AL amyloidosis, where the bone marrow plasma cell (BMPC) burden is often low—up to 20% of patients have <5% clonal plasma cells.9 The downstream overexpression of CCND1 resulting from t(11;14) can be detected on routinely processed bone marrow biopsies using immunohistochemistry (IHC), a widely accessible and cost-effective method, particularly valuable in resource-limited settings.7, 8 However, the diagnostic performance of CCND1 IHC for identifying t(11;14) in AL amyloidosis has not been systematically evaluated. We conducted a single-centre, retrospective study of patients evaluated at the Boston University Amyloidosis Center between January 2020 and June 2025. The study was approved by the Boston University Institutional Review Board and conducted in accordance with the Declaration of Helsinki. Eligible patients met clinicopathological criteria for systemic AL amyloidosis2 and demonstrated morphological evidence of a plasma cell dyscrasia on bone marrow biopsy. Only patients with both FISH testing for t(11;14) and dual IHC staining for CCND1/CD138 were included. FISH was performed on CD138+ enriched plasma cells using a probe specific for the IgH::CCND1 t(11;14)(q13.3;q32.33) rearrangement, with a cut-off value of 1%. Dual CCND1/CD138 IHC was performed on formalin-fixed, paraffin-embedded core biopsy specimens using the Ventana Ultra autostainer to assess CCND1 (SP4-R, Roche) expression in CD138+ (B-A38, Cell Marque) plasma cells after 32 min of antigen retrieval with CC1 buffer (Ventana). Plasma cells were scored as CCND1-positive when ≥5% of CD138+ plasma cells demonstrated nuclear staining of any intensity (Figure 1). The correlation between CCND1 expression and BMPC percentage was evaluated using Pearson and Spearman analyses. Confidence intervals were calculated using the Wilson method. Continuous variables were compared using the Mann–Whitney U-test and a p value <0.05 was considered statistically significant. Among the 130 patients who met inclusion criteria, 61 (47%) were newly diagnosed and untreated. The median age at diagnosis was 65 years (range 33–84 years), and 45 patients (35%) were female. The median BMPC burden was 5% (range 1%–50%; mean 7.5%), and 99 patients (76%) had lambda light chain-restricted disease. Overall, 69 patients (53%) were t(11;14)-positive by FISH (Table 1). CCND1 IHC and FISH t(11;14) results were concordantly positive in 66 patients (51%) and concordantly negative in 54 patients (42%). Discordant CCND1-positive/FISH t(11;14)-negative results were observed in seven patients (5%), all of whom had BMPC burden ≤5%; one harboured a gain of chromosome 11q. Only three patients (2%) were FISH t(11;14)-positive but lacked CCND1 expression by IHC. In the overall cohort, CCND1 IHC demonstrated a sensitivity of 96% (66/69), specificity of 89% (54/61), positive predictive value (PPV) of 90% (66/73) and negative predictive value (NPV) of 95% (54/57) for detecting t(11;14) as determined by FISH. The correlation between CCND1 expression and BMPC percentage was modest, with a Pearson correlation coefficient of r = 0.34 (p < 0.001) and a Spearman rank correlation coefficient of ρ = 0.43 (p < 0.001), indicating a moderate association between these variables. Subgroup analysis showed that CCND1 IHC had excellent diagnostic performance in patients with ≥10% BMPCs (Table 1B), with sensitivity of 97% and specificity of 100% for predicting t(11;14). Even among patients with <10% BMPC, sensitivity remained high at 94%, though specificity was lower at 83%. CCND1 IHC performed consistently across disease settings, with sensitivity ≥94% in both newly diagnosed and relapsed/refractory AL amyloidosis (Table 1C). However, specificity and PPV were higher in newly diagnosed patients, likely on account of their higher median BMPC burden (8% vs. 5%, p < 0.001). These findings support CCND1 IHC as a practical and reliable screening tool for detecting t(11;14) in AL amyloidosis across a range of plasma cell burdens and disease settings. Its high sensitivity (96%) and NPV (95%) allow confident identification of patients who may benefit from BCL-2-targeted therapies, such as venetoclax,2, 6 while enabling exclusion of t(11;14) when CCND1 expression is absent. Importantly, CCND1 expression was detectable even in cases with low BMPC burden, overcoming a major limitation of FISH, which can be hindered by insufficient clonal cell enrichment. The diagnostic performance of CCND1 was maintained across disease settings and was particularly robust when BMPCs exceeded 10%. Our findings align with Tsushima et al.,8 who also reported a small subset of patients with CCND1 expression by IHC despite the absence of t(11;14). In our cohort, seven such cases were observed, including one with an 11q gain. In multiple myeloma, CCND1 overexpression can arise from other genetic alterations, such as 11q gain, trisomy 11, BRAFV600E and RAS pathway mutations, which reduce its PPV and specificity for t(11;14).7, 8, 10 Notably, mutations in the receptor-linked tyrosine kinases (RAS)/mitogen-activated protein kinases (MAPK) pathway have not been identified in AL amyloidosis.11 Among patients in our study who were negative for both t(11;14) by FISH and CCND1 by IHC, 11 patients had trisomy 11 without CCND1 expression, indicating that trisomy 11 alone does not consistently drive CCND1 upregulation. Sometimes, t(11;14) translocation breakpoints may fall outside the regions targeted by standard FISH probes, resulting in false-negative results.12 While these seven cases could represent false-negative t(11;14) FISH testing results, we have not performed next-generation sequencing (NGS)-based tests to confirm this suspicion. NGS has been shown to have 100% concordance with FISH-based testing for detecting t(11;14) in multiple myeloma and can help resolve discordance in such cases.13 Conversely, a minority of t(11;14)-positive cases in our study lacked detectable CCND1 expression by IHC for unclear reasons. This may reflect the higher prevalence of atypical or complex t(11;14) rearrangements in plasma cell disorders—unlike the more typical balanced t(11;14) translocations of mantle cell lymphoma12—which could render the CCND1 protein undetectable by conventional IHC antibodies designed for standard epitopes. Our study has several limitations, including its single-centre, retrospective design and limited generalizability due to institution-specific tissue processing and reporting protocols. The relatively small sample size precluded assessment of treatment outcomes with BCL-2 inhibitors in patients with CCND1 expression by IHC but lacking t(11;14) by FISH, leaving it unknown whether this biologically discordant subgroup derives similar therapeutic benefit as patients with concordant IHC and cytogenetic positivity. Additionally, IHC interpretation is inherently subjective, introducing potential intra- and interobserver variability. We also did not define an optimal CCND1 IHC expression cut-off; a study by Chen et al. proposed a multitiered CCND1 expression scoring system to better predict t(11;14) status in multiple myeloma, highlighting the need for standardized cut-off thresholds.8 In conclusion, CCND1 IHC demonstrates high sensitivity and NPV for detecting t(11;14) in AL amyloidosis and serves as a practical interim screening tool when FISH or molecular assays are unavailable. Confirmatory testing remains essential for definitive detection of t(11;14) and therapeutic decision-making. T.G. and V.S. designed the study, performed data analysis and wrote the manuscript. T.G. and A.S. collected the data. E.J.B. performed and reported the dual cyclin D1/CD138 staining on plasma cells. A.S., E.J.B. and R.E.S interpreted the data and critically revised the manuscript and all authors approved the final version. We acknowledge the contributions of the current and past members of the Amyloidosis Center and Department of Pathology. No funding was available for this project. Vaishali Sanchorawala: Research Support/PI—Celgene, Millenium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, Alexion. Consultant—Pfizer, Janssen, Attralus, GateBio, Abbvie and BridgeBio. Scientific Advisory Board—Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZeneca, Nexcella, Alexion, GSK. The remaining authors declare no competing financial interests. This study was approved by the Boston University Institutional Review Board and adhered to the principles of the Declaration of Helsinki. Data are available upon request.
No takes yet. Share an insight, caveat, or question.
George et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: